All 1 tracked stories fall under one category: earnings. Verbund is most often covered alongside Protagonist Therapeutics, which appears in 1 of these 1 story. Their average consequence score of 5 runs below the beat's 6.1 for that window. Source depth averages 2 original sources per story, versus 2.8 across the same-window beat baseline.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Verbund
All 1 tracked stories fall under one category: earnings. Verbund is most often covered alongside Protagonist Therapeutics, which appears in 1 of these 1 story. Their average consequence score of 5 runs below the beat's 6.1 for that window. Source depth averages 2 original sources per story, versus 2.8 across the same-window beat baseline. We currently track 1 Finance story that mention Verbund, all published on March 17, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 122 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Verbund. Shared-story counts are live from our verified record — not editorial picks.
Austrian utility giant Verbund and biotech firm Protagonist Therapeutics are scheduled to release quarterly results this Wednesday. Investors will be scrutinizing Verbund's hydropower margins and Protagonist's cash position following its recent $400 million deal with Takeda.
Verbund is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.